Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab

Objectives: To evaluate the prognostic value of absolute lymphocyte count (ALC) at diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL). Methods: In a large cohort of patients with DLBCL treated with CHOP (n = 119) or RCHOP (n = 102) in our institution, we evaluated the prognostic valu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2008-12, Vol.81 (6), p.448-453
Hauptverfasser:	Oki, Yasuhiro, Yamamoto, Kazuhito, Kato, Harumi, Kuwatsuka, Yachiyo, Taji, Hirofumi, Kagami, Yoshitoyo, Morishima, Yasuo
Format:	Artikel
Sprache:	eng
Schlagworte:	absolute lymphocyte count Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - administration & dosage Cyclophosphamide - administration & dosage diffuse large B-cell lymphoma Disease-Free Survival Doxorubicin - administration & dosage Female Humans Lymphocyte Count Lymphoma, Large B-Cell, Diffuse - blood Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Predictive Value of Tests Prednisone - administration & dosage prognostic factor Regression Analysis Retrospective Studies Risk Factors Rituximab Survival Rate Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives: To evaluate the prognostic value of absolute lymphocyte count (ALC) at diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL). Methods: In a large cohort of patients with DLBCL treated with CHOP (n = 119) or RCHOP (n = 102) in our institution, we evaluated the prognostic value of ALC at diagnosis with regards to treatment response, overall (OS) and progression‐free survival (PFS). Use of rituximab, all International Prognostic Index (IPI) determinants, β2microglobulin level, presence of B symptoms or bulky disease, and ALC were evaluated. Results: Low ALC (
ISSN:	0902-4441 1600-0609
DOI:	10.1111/j.1600-0609.2008.01129.x